durvalumab
FDA Approves Imfinzi for Muscle-Invasive Bladder Cancer
The FDA has approved Imfinzi with gemcitabine and cisplatin as neoadjuvant treatment for adults with ...
APRIL 2, 2025
FDA Approves Imfinzi for Limited-Stage Small Cell Lung Cancer
The FDA approved Imfinzi for adults with limited-stage small cell lung cancer whose disease has not progressed ...
DECEMBER 6, 2024
FDA Approves Neoadjuvant/Adjuvant Imfinzi for Resectable NSCLC
The FDA has approved Imfinzi, with platinum-containing chemotherapy as neoadjuvant treatment, followed by ...
AUGUST 21, 2024
Antibiotics Can Be Used During Durvalumab Treatment in Biliary Cancer
Antibiotics can be administered without compromising treatment efficacy in patients receiving a durvalumab-based ...
FEBRUARY 27, 2023
Tremelimumab/Durvalumab Combo Promising for Unresectable HCC
Combining a single priming dose of tremelimumab and durvalumab significantly improved overall survival in the ...
MARCH 16, 2022
Imfinzi Approved for First-Line Treatment of Extensive-Stage SCLC
The FDA approved durvalumab (Imfinzi, AstraZeneca) in combination with etoposide and either carboplatin or ...
APRIL 6, 2020
FDA Approves Imfinzi for Advanced Bladder Cancer
Durvalumab is a human monoclonal antibody directed against programmed death ligand-1 (PD-L1), which blocks the ...
MAY 3, 2017